Intensification lessons with modern premixes: From clinical trial to clinical practice

Diabetes Research and Clinical Practice

Volumn 81, Issue SUPPL.1, 2008, Pages

  Guler, Serdar ^a   Vaz, Julius A ^b   Ligthelm, Robert ^c  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Novo Nordisk Pharma Singapore Pte Ltd   (Singapore)

^c EHM Clinic   (Netherlands)

Author keywords

Biphasic insulin aspart 30; Initiation; Intensification; Type 2 diabetes

Indexed keywords

GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

BEDTIME DOSAGE; CLINICAL PRACTICE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE DISCOMFORT; INSULIN TREATMENT; MORNING DOSAGE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT; PATIENT CARE; PATIENT EDUCATION; PHYSICIAN; REFRACTION DISORDER; REVIEW; WEIGHT GAIN;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 48949102502     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.06.010     Document Type: Review

References (32)

1. UK Prospective Disease Study Group (UKPDS). Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
2. Del Prato S. Unlocking the opportunity of tight glycemic control: far from goal. Diabetes Obes. Metab. 7 Suppl. 1 (2005) S1-S4
3. De Leiva A., Toft A.D., and Frandsen K.B. A1c at entry in clinical trials: a systematic review of 93 clinical trials in type 2 diabetes, 2000-2004. Diabetes 55 Suppl. 1 (2006) A109 (457-P)
4. Gough S., Frandsen K.B., and Toft A.D. Failure of insulin monotherapy in patients with type 2 diabetes: a population-based study. Diabetes 55 Suppl. 1 (2006) A114 (477-P)
5. PRESENT Study Group. Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study. Diabetes Obes. Metab. 10 (2008) 212-222
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. Wright A., Burden A.C.F., Paisey R.B., Cull C.A., Holman R.R., and U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK (UKPDS 57). Diabetes Care 25 (2002) 330-336
8. INITIATE Study Group. Initiating insulin therapy in type 2 diabetes. Diabetes Care 28 (2005) 260-265
9. Polonsky K.S., Given B.D., Hirsch L.J., Tillil H., Shapiro E.T., Beebe C., et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 318 (1988) 1231-1239
10. Kann P.H., Wascher T., Zackova V., Moeller J., Medding J.J., Szocs J.A., et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp. Clin. Endocrinol. Diabetes 114 (2006) 527-532
11. Monnier L., Lapinski H., and Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26 (2003) 881-885
12. Garber A.J., Wahlen J., Wahl T., Bressler P., Braceras R., Allen E., et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes. Metab. 8 (2006) 58-66
13. International Diabetes Federation (IDF) Clinical Guidelines Task Force, Brussels, 2005, Available at: http://www.idf.org/webdata/docs/IDFGGT2D.pdf. (accessed 6 February 2008).
14. Davies M., et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28 (2005) 1282-1285
15. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr. Pract. 13 Suppl. 1 (2007) 1-66
16. Raccah D., Bretzel R.G., Owens D., and Riddle M. When basal insulin therapy in type 2 diabetes mellitus is not enough-what next?. Diabetes Metab Res. Rev. 23 (2007) 257-264
17. American Diabetes Association (ADA). Standards of medical care in diabetes, 2007. Diabetes Care 30 Suppl. 1 (2007) S4-S41
18. C.D. Miller, C.S. Barnes, L.S. Phillips, D.C. Ziemer, D.L. Gallina, C.B. et al., Rapid A1c availability improves clinical decision-making in an urban primary care clinic, Diabetes Care 26 (2003) 1158-1163.
19. Riddle M.C., Rosenstock J., Gerich J., and Insulin Glargine 4002 Study Investigators. The treat-to-target trial, randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetes patients. Diabetes Care 26 (2003) 3080-3086
20. Daily G. A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy. Formulary 40 (2005) 114-130
21. Hunt L.M., Valenzuela M.A., and Pugh J.A. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 20 (1997) 292-298
22. Campos C. Treating the whole patient for optimal management of type 2 diabetes: considerations for insulin therapy. South. Med. J. 100 (2007) 804-811
23. Kapitza C., Rave K., Ostrowski K., Heise T., and Heineman L. Reduced postprandial glycaemic excursion with biphasic insulin aspart 30 injected immediately before a meal. Diabet. Med. 21 (2004) 500-501
24. Lund S.S., Tarnow L., Nielsen B.B., Hansen B.V., Pedersen O., Parving H.-H., et al. Effect of BIAsp 30 in combination with oral hypoglycaemic agents on glycaemic regulation in non-obese patients with type-2 diabetes. Diabetologia 9 Suppl. 14 (2006) 600 (abstract 984)
25. Shestakova M., Sharma S.K., Almustafa M., Min K.W., Ayad N., Azar S.T., et al. Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study. Curr. Med. Res. Opin. 23 (2007) 3209-3214
26. Weyer C., Heise T., and Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid acting insulin analog in stable mixture. Diabetes Care 20 (1997) 1612-1614
27. Jacobsen L.V., Bell P., McSorley P., and Kristensen A. Biphasic insulin aspart and biphasic human insulin in type 2 diabetes: a comparison. Diabetes 49 Suppl. 1 (2000) 454 Abstract
28. Boehm B., Home P.D., Behrend C., Kamp N.M., and Lindholm A. Premixed insulin aspart 30 versus premixed human insulin 30/70 twice-daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet. Med. 19 (2002) 393-399
29. Polonsky K.S., Sturis J., and Bell G.I. Non-insulin-dependent diabetes mellitus-a genetically programmed failure of the beta cell to compensate for insulin resistance. N. Engl. J. Med. 334 (1996) 777-783
30. Malone J., Bai S., Campaigne B.N., Reviriego J., and Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet. Med. 22 (2005) 374-381
31. Christiansen J.S., Vaz J.A., Metelko Z., Bogoev M., and Dedov I. Twice-daily biphasic insulin aspart improves postprandial glycaemic control more effectively than twice-daily NPH insulin with low risk of hypoglycaemia in patients with type two diabetes. Diabetes Obes. Metab. 5 (2003) 446-454
32. McSorley P.T., Bell P.M., Jacobsen L.V., Kristensen A., and Lindholm A. Twice daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double blind crossover study in adults with type 2 diabetes mellitus. Clin. Ther. 24 (2002) 530-539